Global Health liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

13.25×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2.67×	2.67×	2.48×	2.44×	2.76×
2.54×	2.54×	2.37×	2.33×	2.65×
127	127	230	425	767
1,048	1,048	914	891	1,007

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MEDANTA₹1,299.70

Global Health Ltd.

· Pharma & Health

₹ CrorePeersMAXHEALTH APOLLOHOSP FORTIS GLAXO ANTHEM AJANTPHARM IPCALAB ABBOTINDIAMcap ₹34,922 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	13.25
Current Ratio	2.76	2.44	2.48	2.67	2.67
Quick Ratio	2.65	2.33	2.37	2.54	2.54
Cash, Equiv & ST Investments	767.2	424.6	230.2	127.3	127.3
Working Capital	1,006.9	891.0	914.3	1,047.8	1,047.8

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.